Johnson & Johnson chairman and CEO Alex Gorsky is stepping down to spend more time at home due to family health issues and, effective on 3 January, will hand over the reins to long-time J&J veteran and current vice chairman Joaquin Duato, the company said on 19 August. Duato will become CEO and be named a member of the J&J board of directors, while Gorsky will transition to executive chairman.
J&J CEO Gorsky Handing Over The Reins To Vice Chairman Duato
Gorsky Will Transition To Executive Chairman
Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Gorsky is stepping down due to a family health issue.
More from Executives On The Move
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
Recent moves in the industry include C-suite changes at Ironwood Pharmaceuticals and Procaps Group, plus Viracta Therapeutics acquires chief executive officer from Molecular Templates.
Recent moves in the industry include changes at the top at Shanghai Bao Pharmaceutical and Alumis, plus Nurix Therapeutics acquires chief commercial officer from Arvinas.
More from Leadership
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The UK giant is forecasting peak sales of $5bn plus